The likelihood for avoidance of five clinically important outcomes in patients with COPD and type 2 inflammation was greater with dupilumab vs. placebo, according to findings from a win ratio analysis ...

A new study published in the Journal of the European Academy of Dermatology and Venerology found dupilumab to have a ...

The FDA granted Priority Review to lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP). Lenacapavir is a long-acting HIV-1 capsid inhibitor administered as a twice-yearly ...

The Health Sciences Authority (HSA) has approved Dupixent (dupilumab) for adults as an add-on maintenance treatment for uncontrolled chronic obstructive pulmonary disease (COPD) characterized by ...

Treatment with JAK inhibitors was associated with a greater risk of infections compared with biologic therapies in patients with atopic dermatitis.

New biologic and targeted therapies are changing the landscape of prurigo nodularis care, offering sustained relief and ...

The chronic pruritus market is expected to grow across the 7MM, driven by the introduction of innovative therapies like ...

Current eosinophilic esophagitis treatment guidelines include dietary modifications, medications, and endoscopic procedures.

New findings suggest asthma may be reversible in some cases, offering hope for long-term remission and a shift in treatment ...

Patients with atopic dermatitis had an increased risk for COVID-19 infection despite age and sex, and some comorbidities were linked to a greater risk.

Slow progress, pipeline uncertainty & lack of catalysts weigh despite strong cash. Click to read why KYMR stock is a Hold.

Many people with COPD don’t notice the early symptoms. Here's how to spot subtle signs, get diagnosed early, and explore new ...